Companies: 10,795·Total market cap: $144.5T
Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTONASDAQHealthcare
$0.30
+$0.30(+100.00%)
Market Cap$1133556
P/E Ratio—
52W High$0.4158
52W Low$0.3
Shares OutstandingFinancialsRevenue

Altamira Therapeutics Ltd. (CYTO) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

CYTO · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
491,000▲ +978.27% YoY Change
FY · as of Dec 31, 2023 · Reported in CHF
vs 45,536 in FY 2022
Diluted Shares Outstanding
491,258
incl. options, RSUs, convertibles
Dilution Spread
+0.05%
Diluted vs Basic
YoY Change
+978.27%
year-over-year
Float (Free Float)
2.7M
publicly tradable shares
70.3% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+219.6%
2020 → 2023
5-Year CAGRincreasing
+162.0%
2018 → 2023
10-Year CAGRincreasing
+101.2%
2013 → 2023
ⓘ

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2023Latest
Diluted Shares: 491,258
491,000
+978.27%
FY 2022
Diluted Shares: 45,536
45,536
+37.50%
FY 2021
Diluted Shares: 33,116
33,116
+120.26%
FY 2020
Diluted Shares: 15,035
15,035
+3.37%
FY 2019
Diluted Shares: 14,545
14,545
+265.91%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs CYTO
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
Altamira Therapeutics Ltd.CYTO
Altamira Therapeutics Ltd.YOU
491,000—

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Altamira Therapeutics Ltd. (CYTO) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2023, Altamira Therapeutics Ltd. reports 491,000 basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Altamira Therapeutics Ltd.'s basic shares outstanding (491,000) represents currently issued shares. Diluted shares outstanding (491,258) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.05%.

Shares Outstanding vs. Float (Free Float)

Altamira Therapeutics Ltd.'s float is 2.7M (70.3% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float2.7M(70.3%)
Outstanding3.8M

ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · CHF

About shares outstanding & methodology

Altamira Therapeutics Ltd. (CYTO) shares outstanding history from 2012 to 2023. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Altamira Therapeutics Ltd. shares outstanding for the fiscal year ending December 31, 2023 were 491,000, a 978.27% increase year-over-year. Altamira Therapeutics Ltd. FY 2023 shares outstanding were 491,000, a +978.27% increase from FY 2022.

Altamira Therapeutics Ltd. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +101.2% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.
Market capSplitsEarningsFinancials (Income)Cash on handFree cash flowNet incomePrice history

Frequently asked questions

CYTO shares outstanding · 4 questions

As of December 31, 2023, Altamira Therapeutics Ltd. (CYTO) has approximately 491,000 basic shares outstanding and 491,258 diluted shares outstanding. This represents a +978.27% year-over-year increase from FY 2022 (45,536). The increase may reflect equity compensation issuances or secondary offerings.

CYTO shares outstandinghow many shares does CYTO haveCYTO basic shares 2023CYTO diluted shares

▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Altamira Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09